ANEMIA RESPONSE TO MOMELOTINIB IN MYELOFIBROSIS: APPLICATION OF THE NEW 2024 IWG-ELN CRITERIA IN CLINICAL PRACTICE (SIE 2026) - Oct 6, 2026 - Abstract #SP128; "20 pts (69%) were JAKi-pretreated (95% ruxolitinib, Rux). Our real word application of 2024 IWG-ELN anemia criteria show progressive ORR in TD patients and stable TI in non-TD, mirroring clinical trials. Favorable safe- ty and low discontinuation support MMB efficacy in real- -world practice; predictive factors for AR durability require further study."
Clinical • Anemia • Hematological Disorders • Infectious Disease • Myelofibrosis • Thrombocytopenia • ACVR1
|
|
E. M. Elli1; F. Cavalca1; E. Masedu1,2; M. Ferrario1,2; C. Gambacorti-Passerini1,2; F. Duca1,2
|